This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodriguez, I. Articles by Woosley, R. L. Search for Related Content PubMed PubMed Citation Articles by Rodriguez, I. Articles by Woosley, R. L. Related Collections Biochemistry and metabolism Gene expression Ion channels/membrane transport

(Circulation. 1999;99:472-474.)
© 1999 American Heart Association, Inc.

Editorials

P-Glycoprotein in Clinical Cardiology

Ignacio Rodriguez, MD; Darrell R. Abernethy, MD, PhD; Raymond L. Woosley, MD, PhD

From the Division of Clinical Pharmacology, Department of Pharmacology, Georgetown University Medical Center, Washington, DC.

Correspondence to Raymond L. Woosley, MD, PhD, Department of Pharmacology, Georgetown University Medical Center, Room SE 402, Medical Dental Bldg, 3900 Reservoir Rd NW, Washington, DC 20007. E-mail woosleyr@gunet.georgetown.edu

Key Words: Editorials • glycoproteins • genes • drug resistance • pharmacokinetics

Ever since Juliano and Ling first described P-glycoprotein (P-gp) in 1975,¹ it has become an important focus of research. P-gp is a member of the ATP-binding cassette (ABC) superfamily of proteins that is highly conserved in distantly related species (from simple eukaryotes to vertebrates).² These similarities across species suggest that P-gp plays an important role in physiological processes in normal cells. One established function is its active transport of drugs out of the cell against a concentration gradient using ATP as an energy source, which is unusual because unlike most energy-dependent pumps, it has very little substrate specificity. Humans have 2 known P-gp encoding genes, MDR1 (class I) and MDR2 (class III), both localized in chromosome 7.³ The first has been associated with the phenomenon of multiple drug resistance (MDR),⁴ and the second serves to transport phospholipids into the bile.⁵ Cloning and sequencing of the MDR gene led to the identification of the composition and structure of P-gp,⁶ which consists of 2 membrane-bound domains (each with 6 transmembrane segments) and 2 nucleotide-binding domains that bind and hydrolyze ATP.⁴

The initial and major emphasis of P-gp research was to explain the occurrence of multidrug resistance in tumors that were initially exposed to a single drug and with time developed resistance to a wide range of other unrelated drugs. Concurrent with the investigation of tumor drug resistance, there have been studies linking this MDR protein with phase I and phase II drug biotransformations,⁷ and others have examined the expression and function of . . . [Full Text of this Article]

This article has been cited by other articles:

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				M. Weiss and W. Kang P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694. [Abstract] [Full Text] [PDF]

				J.L. Bauman The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K93 - K100. [Abstract] [PDF]

				Y.-H. Han, D. H. Sweet, D.-N. Hu, and J. B. Pritchard Characterization of a Novel Cationic Drug Transporter in Human Retinal Pigment Epithelial Cells J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 450 - 457. [Abstract] [Full Text]